EUGIA Pharma Specialities Limited – FDA 483, May 3, 2024
EUGIA Pharma Specialities Limited, a sterile drug manufacturing site in Bhiwadi, India, was cited for significant deficiencies in its aseptic processing, quality control, and contamination prevention systems. The inspection revealed failures in following procedures to prevent microbiological contamination, inadequate validation of aseptic processes, and insufficient investigation into discrepancies and out-of-specification results. Additionally, the firm lacked proper controls to prevent cross-contamination between different pharmaceutical products and exhibited shortcomings in environmental monitoring and cleaning procedures.
ID · 2100530d-b507-419b-8d24-6840d66f73b3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.